InterMune, Inc. (ITMN) Reports First Quarter 2013 Financial Results and Business Highlights
4/25/2013 6:31:20 AM
More...
|
InterMune, Inc. (ITMN) to Release First Quarter Financial Results on April 24
4/17/2013 6:58:31 AM
More...
|
InterMune, Inc. (ITMN) Release: Esbriet® (pirfenidone) Receives Positive Final Appraisal Determination From National Institute for Clinical Excellence (NICE) for Idiopathic Pulmonary Fibrosis (IPF)
3/21/2013 10:27:03 AM
More...
|
InterMune, Inc. (ITMN) Reports Fourth Quarter and Full Year 2012 Financial Results and Business Highlights
2/22/2013 7:19:18 AM
More...
|
Royalty Deal May Settle Lawsuit Over InterMune, Inc. (ITMN) Lung Drug
2/20/2013 8:04:30 AM
More...
|
Sean P. Nolan Joins InterMune, Inc. (ITMN) as Executive Vice President and Chief Business Officer
2/15/2013 6:53:01 AM
More...
|
InterMune, Inc. (ITMN) to Release Fourth Quarter Financial Results on February 21
2/11/2013 6:30:15 AM
More...
|
InterMune, Inc. (ITMN) Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Debt
1/15/2013 9:20:48 AM
More...
|
InterMune, Inc. (ITMN) Reports Preliminary Fourth Quarter 2012 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
1/4/2013 6:42:52 AM
More...
|
InterMune, Inc. (ITMN) to Present at J. P. Morgan Healthcare Conference
1/2/2013 6:46:26 AM
More...
|
|